Crescentic Fibrillary Glomerulonephritis with Severe AKI: Renal Recovery After Rituximab Induction (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0741; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "She received intravenous methylprednisolone 500 mg daily for three days, oral prednisone taper, and rituximab 1 g induction (three weekly doses)...There is no agreed treatment; published cases describe corticosteroids, cyclophosphamide, and rituximab in various combinations...Pulse-dose and high-dose oral steroids were necessary up front, but the patient was readmitted with steroid-induced psychosis, and the AKI briefly returned. Tapering steroids more quickly once rituximab has had time to act might have spared her the readmission."
CNS Disorders • Diabetes • Diabetic Nephropathy • Gastroenterology • Glomerulonephritis • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus
|
|
Amanda Joy Cox Renfrow; Salwa Khan; Ujjwala Murari; Amit Kaushal; Rebecca J. Schmidt
|